biotx.ai Target Discovery Collaboration
Heart Failure
Key Facts
About HeartBeat.bio
HeartBeat.bio is a TechBio company developing a next-generation platform for cardiac drug discovery based on its proprietary human heart organoids, called Cardioids. These 3D models replicate the architecture and function of human heart chambers, enabling scalable, high-throughput disease modeling and compound screening. The company has secured strategic collaborations with major pharmaceutical and technology partners, such as Boehringer Ingelheim and Molecular Devices, and raised €4.5 million in a Pre-Series A round to scale its platform. Its business model centers on providing a technology platform and research services to accelerate and de-risk drug development for heart failure, cardiomyopathies, and other cardiac conditions.
View full company profileTherapeutic Areas
Other Heart Failure Drugs
| Drug | Company | Phase |
|---|---|---|
| Cardiac Cell Therapy Program | StemCardia | Pre-clinical |
| NTP42 | ATXA Therapeutics | Preclinical |
| Heart Failure Trial | Clinical Investigation Specialists | Not Specified |
| INPEFA (sotagliflozin) | Lexicon Pharmaceuticals | Approved |
| MyCardia™ | Avery Therapeutics | Pre-clinical |
| Cardiac Assist Device | Second Heart Assist | Pre-clinical |
| Isosorbide Dinitrate/Hydralazine HCl Tablets | i3 Pharmaceuticals | Approved |
| TLT-101 | TikkunLev Therapeutics | Pre-clinical |
| Undisclosed Heart Regeneration Program | Animatus Biosciences | Pre-clinical |
| AFteR Registry | Occlutech | N/A (Registry) |
| Surlorian | RyCarma Therapeutics | Phase 2 |
| Coronary Sinus Reduction | Shockwave Medical | Unknown |